One in seven people with high blood pressure may have this condition
For generations, a hormonal condition hiding behind ordinary high blood pressure has left millions of patients with little more than a single aging medication and its burdens. Now, researchers publishing in The New England Journal of Medicine have identified a new drug that may finally offer an alternative for those with primary aldosteronism — a condition affecting as many as one in seven hypertension patients, most of whom never receive the correct diagnosis. The discovery does not merely add a name to a prescription list; it reopens a clinical conversation that has been largely closed for decades, and with it, the possibility of genuinely controlled lives for people whose cardiovascular risk has quietly accumulated.
- Millions of people are being treated for high blood pressure without anyone identifying the true hormonal cause — primary aldosteronism — leaving them exposed to preventable heart attacks and strokes.
- Spironolactone, the only approved treatment for decades, fails too many patients through intolerable side effects or insufficient effectiveness, creating a therapeutic dead end with serious consequences.
- A new drug published in one of medicine's most prestigious journals now offers physicians a real alternative, breaking open a treatment landscape that has been frozen since the era the original medication was developed.
- The challenge shifts from discovery to delivery — integrating the new therapy into clinical practice, improving diagnostic recognition, and ensuring access for the patients who need it most.
A new medication may reshape treatment for millions of people whose high blood pressure stems not from lifestyle or genetics alone, but from a specific hormonal malfunction. Researchers have published findings in The New England Journal of Medicine pointing to a drug that could meaningfully improve outcomes for patients who have long been underserved by existing options.
Primary aldosteronism occurs when the adrenal glands overproduce aldosterone, causing the body to retain salt and fluid and driving blood pressure to dangerous levels. According to Wenyu Huang, an associate professor at Northwestern University's Division of Endocrinology, as many as one in seven people with hypertension may have this condition — yet it remains chronically underdiagnosed, meaning the true cause of their illness goes unaddressed while treatment targets only the symptom.
For decades, spironolactone has been the sole approved medication for this condition. Its limitations are well documented: many patients cannot tolerate its side effects, and others find it insufficiently effective, particularly when doses cannot safely be raised. The result has been a population of patients with persistently uncontrolled blood pressure and elevated risk of cardiovascular events, trapped by the constraints of a single aging drug.
The new research signals a genuine turning point. Physicians will now have an alternative to offer patients who have struggled with spironolactone, and the scale of the problem makes this significant — primary aldosteronism is the most common endocrine cause of hypertension worldwide. What remains is the practical work: bringing the new treatment into clinical use, sharpening diagnostic recognition, and ensuring that the patients who stand to benefit can actually reach it.
A new medication may reshape treatment for millions of people living with high blood pressure caused by a specific hormonal imbalance. Researchers publishing in The New England Journal of Medicine have identified a drug that could offer real improvement for patients whose condition has been difficult to manage with existing therapies.
Primary aldosteronism is what happens when the adrenal glands overproduce a hormone called aldosterone. The body responds by holding onto salt and fluid, which drives blood pressure up and can trigger serious heart problems down the line. The condition is deceptively common—according to Wenyu Huang, an associate professor of medicine at Northwestern University's Division of Endocrinology, Metabolism and Molecular Medicine, as many as one in seven people with high blood pressure may actually have primary aldosteronism. Yet it remains underdiagnosed, meaning countless patients are being treated for hypertension without anyone identifying the true underlying cause.
For decades, doctors have had only one approved medication to work with: spironolactone. It was developed long ago and has been the sole option available. But spironolactone comes with real limitations. Many patients cannot tolerate its side effects, and others find it simply does not work well enough, particularly when doctors cannot safely increase the dose to effective levels. This has left a significant population of patients stuck—their blood pressure remains inadequately controlled, and their risk of heart attack or stroke stays elevated.
The emergence of a new drug represents a genuine shift in what becomes possible for these patients. Rather than accepting the constraints of a single medication developed generations ago, physicians will now have an alternative that may work better for people who have struggled with spironolactone. The research published in one of medicine's most prestigious journals suggests this new approach can meaningfully improve how well doctors can manage the condition.
What makes this development particularly significant is the scale of the problem it addresses. Primary aldosteronism is not rare. It is the most common endocrine cause of high blood pressure. Millions of people worldwide carry this diagnosis, many without knowing it. For those who do know, the limited treatment options have meant accepting either inadequate blood pressure control or medication side effects they would rather avoid. A new therapeutic option expands what doctors can offer and gives patients a genuine choice.
The path forward will involve integrating this new medication into clinical practice, training physicians to recognize primary aldosteronism more reliably, and ensuring patients who might benefit can access the treatment. The research foundation is now in place. What remains is the practical work of translating this discovery into better health outcomes for the millions of people whose blood pressure has been difficult to control.
Notable Quotes
Primary aldosteronism is the most common cause of hypertension caused by an endocrine disorder— Dr. Wenyu Huang, Northwestern University
The Hearth Conversation Another angle on the story
Why has primary aldosteronism been so hard to diagnose if it's affecting one in seven people with high blood pressure?
Because it requires specific testing—you can't just measure blood pressure and know what's causing it. Many doctors never think to look for it, so they treat the symptom without finding the root cause.
And spironolactone has been the only option for how long?
Decades. It's an old drug, effective for some people, but it has real drawbacks. Some patients can't tolerate the side effects. Others need doses that are too high to be safe, so they end up underdosed and their blood pressure stays uncontrolled.
So this new drug—does it work differently, or is it just a better version of the same thing?
The source doesn't specify the mechanism, but the fact that it's being published in The New England Journal of Medicine suggests it represents a meaningful advance. It's not just a minor tweak—it's a genuinely new option.
What happens to patients right now who have primary aldosteronism but can't tolerate spironolactone?
They live with inadequate blood pressure control and elevated cardiovascular risk. That's the human cost of having only one treatment option for decades. This new drug changes that calculus.
Will this drug be available soon?
The research is published, which is the scientific foundation. But getting it into actual clinical practice—that takes time. Doctors need to learn about it, patients need access to it, insurance needs to cover it. The discovery is here. The rollout is what comes next.